




Procainamides and Metabolites on ZORBAX XDB-C8

Application
Pharmaceutical
Robert Ricker

Procainamide is prescribed as an anti-arrhythmic medication for cardiac patients. It has a major metabolite, n-acetylprocainamide, which also appears in this separation, along with n-propionylprocainamide. The USP XXIII assay for this drug product is performed at pH 7.5. At high pH, more silanol groups are ionized and are active to interact with analyte. The ZORBAX Eclipse packings (e.g., XDB-C8) are better suited to intermediate-pH applications because their extra-dense bonding and double endcapping better shields active silanols.

Highlights

- The ZORBAX XDB-C8 provides good peak shape and resolution of procainamides at the USP-recommended mobile-phase pH of 7.0 or higher.



Conditions:
ZORBAX XDB-C8 (4.6 x 150 mm) (Agilent P/N: 993967-906)
Mobile Phase: (90:10) 20 mM Na₂HPO₄ (pH 7.0): ACN
Injection 5µL, 1.5 mL/min, 40°C, Detect. UV (254 nm)



Agilent Technologies

*Robert Ricker is an application chemist
based at Agilent Technologies, Wilmington,
Delaware.*

For more information on our products and
services, visit our website at:
www.agilent.com/chem

Copyright© 2002 Agilent Technologies, Inc.
All Rights Reserved. Reproduction,
adaptation or translation without prior
written permission is prohibited, except as
allowed under the copyright laws.

Agilent shall not be liable for errors
contained herein or for incidental or
consequential damages in connection with
the furnishing, performance, or use of this
material.

Information, descriptions, and specifications
in this publication are subject to change
without notice.

Printed in the USA
April 25, 2002
5988-6426EN



Agilent Technologies